Global Cancer Vaccines Market 2015-2019 - Strategic Alliances with Dendreon, GSK & Merck Dominating

News provided by

Jul 07, 2015, 08:35 ET

DUBLIN, June 30, 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/tdswhd/global_cancer) has announced the addition of the "Global Cancer Vaccines Market 2015-2019" report to their offering.

The global cancer vaccines market to grow at a CAGR of 27.24% over the period 2014-2019.

Cancer vaccines are biological preparations that stimulate or strengthen a person's immune system against cancer. Cancer vaccines are usually administered intravenously. They can be used in both adults and children. The vaccines can be broadly classified into two: prophylactic and therapeutic vaccines. Prophylactic vaccines are used for the prevention of cancer, whereas therapeutic vaccines are used for treatment of cancer.

This report covers the present scenario and the growth prospects of the global cancer vaccines market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various therapeutic and prophylactic cancer vaccines.

Strategic alliances not only help a vendor increase its market penetration but they also enhance the vendor's product portfolio. For instance, GAVI Alliance aims to immunize about 2-million females in developing regions in 2015 using the HPV vaccines Cervarix and Gardasil, which are supplied at a low cost by GlaxoSmithKline and Merck. In 2015, Bristol-Myers Squibb collaborated with Bavarian Nordic to develop Prostvac, a therapeutic vaccine for the treatment of prostate cancer. Together, in 2015, Advaxis and Incyte evaluated ADXS-HPV using Incyte's investigational oral indoleamine 2,3-dioxygenase 1 inhibitor, epacadostat. In 2014, Boehringer Ingelheim and CureVac entered into an agreement to develop and commercialize a lung cancer vaccine CV9202 using CureVac's RNA technology, RNActive.

According to the report, cancer is a leading cause of deaths worldwide. According to the World Health Organization, 14-million incidences of cancer and 8.2-million cancer deaths were recorded in 2012. Lung, prostate, colorectal, cervical, and breast cancers remain the most common forms of cancer. Thus, there is a rise in demand for vaccines to prevent and treat cancers.

Further, the report states that cold chain, or temperature-controlled supply chain, management is a major challenge for this market.

Key Vendors

- Dendreon
- GlaxoSmithKline
- Merck

Other Prominent Vendors

- Aduro BioTech
- Advantagene
- Advaxis
- Agenus
- AlphaVax
- Altor BioScience
- Amgen
- Antigen Express
- Argos Therapeutics
- AVAX Technologies
- Bavarian Nordic
- Biothera
- Bristol-Myers Squibb
- Cytos
- Galena Biopharma
- Genexine
- GlobeImmune
- ImmunoCellular Therapeutics
- Immutep
- Inovio Pharmaceuticals
- Isa Pharmaceuticals
- Juvaris Biotherapeutics
- MedImmune
- NewLink Genetics
- Northwest Biotherapeutics
- NovaRx
- OncoThyreon
- Progenics
- Provectus Biopharmaceuticals
- Sanofi
- Sotio
- Transgene
- Ubivac